David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses a Phase Ib trial (NCT03248479) of magrolimab, a novel anti-CD47 antibody, plus azacitidine in untreated acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. By blocking CD47, a macrophage immune checkpoint, magrolimab can induce tumor cell phagocytosis. Stemming from evidence of synergistic activity between magrolimab and azacitidine in AML, the dose-escalation trial was designed to investigate safety and efficacy of the combination. Results showed that the treatment was well tolerated, and adverse event occurrence was like that seen with azacitidine monotherapy. The results showed that 65% of efficacy evaluable patients achieved a treatment response, with 44% reaching complete remission (CR). Promising efficacy was also seen in TP53-mutant patients, a population who do not respond well to standard of care azacitidine plus venetoclax therapy. With encouraging initial results, enrollment is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.